Impact of a clinical pharmacokinetic service on patients treated with aminoglycosides: A cost-benefit analysis

Christopher J. Destache, Sharon K. Meyer, Marvin J. Bittner, Kenneth G. Hermann

Research output: Contribution to journalArticle

75 Citations (Scopus)

Abstract

In a prospective, randomized study, 75 adults receiving aminogly-cosides were followed by a clinical pharmacokinetic service and 70 followed as controls. The two groups were similar in age, gender, height, and APACHE II score. A cost-to-charge ratio was used to derive direct costs of hospitalization and calculate cost-benefit. Excluded from this comparison were patients with incomplete acceptance of pharmacokinetic service recommendations and patients followed by other clinical pharmacists. Pharmacokinetic service patients had shorter hospitalizations (322.67 ± 270.28 h; controls 442.89 ± 536.81, p = 0.087) and febrile periods (50.05 ± 79.38 h; controls 92.23 ± 122.50, p <0.05). More pharmacokinetic service patients had adequate peak levels. Pharmacokinetic service direct costs were lower (7,102.56 ± 9,898.19; controls 13,758.64 ± 22,874.31, p <0.05). Calculated direct cost of the service was 85.00/patient. Annual savings for 500 patients is 2,220,540.00.

Original languageEnglish
Pages (from-to)419-426
Number of pages8
JournalTherapeutic Drug Monitoring
Volume12
Issue number5
StatePublished - 1990

Fingerprint

Cost benefit analysis
Pharmacokinetics
Aminoglycosides
Cost-Benefit Analysis
Direct Service Costs
Costs
Hospitalization
Costs and Cost Analysis
APACHE
Pharmacists
Fever
Prospective Studies

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)
  • Pharmacology
  • Biochemistry, Genetics and Molecular Biology(all)
  • Biochemistry
  • Health, Toxicology and Mutagenesis
  • Public Health, Environmental and Occupational Health
  • Toxicology

Cite this

Impact of a clinical pharmacokinetic service on patients treated with aminoglycosides : A cost-benefit analysis. / Destache, Christopher J.; Meyer, Sharon K.; Bittner, Marvin J.; Hermann, Kenneth G.

In: Therapeutic Drug Monitoring, Vol. 12, No. 5, 1990, p. 419-426.

Research output: Contribution to journalArticle

Destache, Christopher J. ; Meyer, Sharon K. ; Bittner, Marvin J. ; Hermann, Kenneth G. / Impact of a clinical pharmacokinetic service on patients treated with aminoglycosides : A cost-benefit analysis. In: Therapeutic Drug Monitoring. 1990 ; Vol. 12, No. 5. pp. 419-426.
@article{de682ddf07b14b8b9585f52119d2d09e,
title = "Impact of a clinical pharmacokinetic service on patients treated with aminoglycosides: A cost-benefit analysis",
abstract = "In a prospective, randomized study, 75 adults receiving aminogly-cosides were followed by a clinical pharmacokinetic service and 70 followed as controls. The two groups were similar in age, gender, height, and APACHE II score. A cost-to-charge ratio was used to derive direct costs of hospitalization and calculate cost-benefit. Excluded from this comparison were patients with incomplete acceptance of pharmacokinetic service recommendations and patients followed by other clinical pharmacists. Pharmacokinetic service patients had shorter hospitalizations (322.67 ± 270.28 h; controls 442.89 ± 536.81, p = 0.087) and febrile periods (50.05 ± 79.38 h; controls 92.23 ± 122.50, p <0.05). More pharmacokinetic service patients had adequate peak levels. Pharmacokinetic service direct costs were lower (7,102.56 ± 9,898.19; controls 13,758.64 ± 22,874.31, p <0.05). Calculated direct cost of the service was 85.00/patient. Annual savings for 500 patients is 2,220,540.00.",
author = "Destache, {Christopher J.} and Meyer, {Sharon K.} and Bittner, {Marvin J.} and Hermann, {Kenneth G.}",
year = "1990",
language = "English",
volume = "12",
pages = "419--426",
journal = "Therapeutic Drug Monitoring",
issn = "0163-4356",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Impact of a clinical pharmacokinetic service on patients treated with aminoglycosides

T2 - A cost-benefit analysis

AU - Destache, Christopher J.

AU - Meyer, Sharon K.

AU - Bittner, Marvin J.

AU - Hermann, Kenneth G.

PY - 1990

Y1 - 1990

N2 - In a prospective, randomized study, 75 adults receiving aminogly-cosides were followed by a clinical pharmacokinetic service and 70 followed as controls. The two groups were similar in age, gender, height, and APACHE II score. A cost-to-charge ratio was used to derive direct costs of hospitalization and calculate cost-benefit. Excluded from this comparison were patients with incomplete acceptance of pharmacokinetic service recommendations and patients followed by other clinical pharmacists. Pharmacokinetic service patients had shorter hospitalizations (322.67 ± 270.28 h; controls 442.89 ± 536.81, p = 0.087) and febrile periods (50.05 ± 79.38 h; controls 92.23 ± 122.50, p <0.05). More pharmacokinetic service patients had adequate peak levels. Pharmacokinetic service direct costs were lower (7,102.56 ± 9,898.19; controls 13,758.64 ± 22,874.31, p <0.05). Calculated direct cost of the service was 85.00/patient. Annual savings for 500 patients is 2,220,540.00.

AB - In a prospective, randomized study, 75 adults receiving aminogly-cosides were followed by a clinical pharmacokinetic service and 70 followed as controls. The two groups were similar in age, gender, height, and APACHE II score. A cost-to-charge ratio was used to derive direct costs of hospitalization and calculate cost-benefit. Excluded from this comparison were patients with incomplete acceptance of pharmacokinetic service recommendations and patients followed by other clinical pharmacists. Pharmacokinetic service patients had shorter hospitalizations (322.67 ± 270.28 h; controls 442.89 ± 536.81, p = 0.087) and febrile periods (50.05 ± 79.38 h; controls 92.23 ± 122.50, p <0.05). More pharmacokinetic service patients had adequate peak levels. Pharmacokinetic service direct costs were lower (7,102.56 ± 9,898.19; controls 13,758.64 ± 22,874.31, p <0.05). Calculated direct cost of the service was 85.00/patient. Annual savings for 500 patients is 2,220,540.00.

UR - http://www.scopus.com/inward/record.url?scp=0025007982&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025007982&partnerID=8YFLogxK

M3 - Article

C2 - 2127324

AN - SCOPUS:0025007982

VL - 12

SP - 419

EP - 426

JO - Therapeutic Drug Monitoring

JF - Therapeutic Drug Monitoring

SN - 0163-4356

IS - 5

ER -